Novartis Institute for Tropical Diseases
... graduate students coming from all over the world, mostly from developing countries. continued ...
... graduate students coming from all over the world, mostly from developing countries. continued ...
Cholesterol Management in Coronary Heart Disease Patients
... Performance can be improved in a number of ways in your pharmacy. First off, it is imperative that you are regularly talking to your patients to learn about their health conditions, both past and present. You can start by recognizing those patients who have coronary artery disease based on their med ...
... Performance can be improved in a number of ways in your pharmacy. First off, it is imperative that you are regularly talking to your patients to learn about their health conditions, both past and present. You can start by recognizing those patients who have coronary artery disease based on their med ...
Fact Sheet - Redwood Caregiver Resource Center
... glatiramer acetate (Copaxone), widely known as the "ABC" drugs, can be effective in modifying the course of the disease and help slow disease progression for many people. While these medications are currently approved by the FDA only for people who have relapsing-remitting MS, interferon beta-1b and ...
... glatiramer acetate (Copaxone), widely known as the "ABC" drugs, can be effective in modifying the course of the disease and help slow disease progression for many people. While these medications are currently approved by the FDA only for people who have relapsing-remitting MS, interferon beta-1b and ...
For Immediate release - Aplastic Anemia and MDS International
... hemoglobinuria and single lineage cytopenias (e.g., large granular lymphocyte leukemia, pure red cell aplasia). Despite the progress achieved in recent decades, the mortality rate for these diseases remains high. Some of these diseases are still incurable and result in chronic morbidity throughout t ...
... hemoglobinuria and single lineage cytopenias (e.g., large granular lymphocyte leukemia, pure red cell aplasia). Despite the progress achieved in recent decades, the mortality rate for these diseases remains high. Some of these diseases are still incurable and result in chronic morbidity throughout t ...
Nanoparticle theories slowly turn into practice
... more docetaxel to the tumor site than an equivalent dose of However, many companies are starting to scale up manuinfused Taxotere, with greater efficacy and less severe side effacturing, producing hundreds of grams or even kilograms, fects. The nanoparticle seeks out prostate-specific membrane Grodz ...
... more docetaxel to the tumor site than an equivalent dose of However, many companies are starting to scale up manuinfused Taxotere, with greater efficacy and less severe side effacturing, producing hundreds of grams or even kilograms, fects. The nanoparticle seeks out prostate-specific membrane Grodz ...
- Raremark: about us
... direction, more guidance from regulators is needed on how industry can ensure PROMs are more widely accepted in research applications. Time is of the essence Drug developers are often working to ...
... direction, more guidance from regulators is needed on how industry can ensure PROMs are more widely accepted in research applications. Time is of the essence Drug developers are often working to ...
PowerPoint_Template - National Multiple Sclerosis Society
... 1/750 for the general population (0.1%) 1/40 for person with a close relative with MS (3%) 1/4 for an identical twin (25%) • 20% of people with MS have a blood relative with MS The risk is higher in any family in which there are several family members with the disease (aka multiplex families) ...
... 1/750 for the general population (0.1%) 1/40 for person with a close relative with MS (3%) 1/4 for an identical twin (25%) • 20% of people with MS have a blood relative with MS The risk is higher in any family in which there are several family members with the disease (aka multiplex families) ...
Systemic Lupus Erythematosus
... symptoms. Azathioprine is most often used in dogs; chlorambucil is frequently chosen for cats. Immunosuppressive therapy requires frequent monitoring by your veterinarian for possible side effects. After your pet's disease is controlled and the symptoms are reduced or resolved, the dose of the drug ...
... symptoms. Azathioprine is most often used in dogs; chlorambucil is frequently chosen for cats. Immunosuppressive therapy requires frequent monitoring by your veterinarian for possible side effects. After your pet's disease is controlled and the symptoms are reduced or resolved, the dose of the drug ...
PATIENT`S NAME:
... AGE: _______ HEIGHT: ____________ WEIGHT: ____________ NUMBER OF CHILDREN: _____ Part I HISTORY The following questions are to be filled out by the patient. Check box YES or NO. Any positive response will be discussed with you by your doctor. LUNGS Born with any lung disease Cough or cold (at presen ...
... AGE: _______ HEIGHT: ____________ WEIGHT: ____________ NUMBER OF CHILDREN: _____ Part I HISTORY The following questions are to be filled out by the patient. Check box YES or NO. Any positive response will be discussed with you by your doctor. LUNGS Born with any lung disease Cough or cold (at presen ...
Navigating the Clinical Trials Pathway
... conducted with people who volunteer to take part. Each study answers scientific questions and tries to find better ways to prevent, screen for, diagnose, or treat a disease. People who take part in cancer clinical trials have an opportunity to contribute to knowledge of, and ...
... conducted with people who volunteer to take part. Each study answers scientific questions and tries to find better ways to prevent, screen for, diagnose, or treat a disease. People who take part in cancer clinical trials have an opportunity to contribute to knowledge of, and ...
Adult Onset Still`s Disease
... Triggers: infections or medications Treatment: cyclosporine, cyclophosphamide and steroids, in addition to typical AOSD therapy (see below) Incidence: Estimated at 8% of AOSD patients; more common in AOSD than other autoimmune diseases ...
... Triggers: infections or medications Treatment: cyclosporine, cyclophosphamide and steroids, in addition to typical AOSD therapy (see below) Incidence: Estimated at 8% of AOSD patients; more common in AOSD than other autoimmune diseases ...
complementary and alternative
... Glucosamine sulfate may also have anti-inflammatory effects. In vitro studies suggest that it inhibits cellular production of inflammatory mediators, a reduction in inflammation has been demonstrated in a rat adjuvant arthritis model. Clinical trials of glucosamine sulfate have generally been small ...
... Glucosamine sulfate may also have anti-inflammatory effects. In vitro studies suggest that it inhibits cellular production of inflammatory mediators, a reduction in inflammation has been demonstrated in a rat adjuvant arthritis model. Clinical trials of glucosamine sulfate have generally been small ...
prevention of infectious diseases, emerging food-, water
... present call due to their high burden in the LAC region. Emerging food, water and vector-borne diseases still have high rates of morbidity and in specific cases high mortality rate. They often are associated to difficulties for early detection of the infection, therapeutic limitations, areas without ...
... present call due to their high burden in the LAC region. Emerging food, water and vector-borne diseases still have high rates of morbidity and in specific cases high mortality rate. They often are associated to difficulties for early detection of the infection, therapeutic limitations, areas without ...
Risk factors for tuberculosis exposure should
... ALTERNATE TREATMENT REGIMEN: Rifampin at 10-20 mg/kg po daily for 6 months can be given in cases of INH intolerance or for contacts of patients with INH resistant TB. Drug sensitivities should always be checked when the source case is known. Rifampin will turn urine and other body fluids orange and ...
... ALTERNATE TREATMENT REGIMEN: Rifampin at 10-20 mg/kg po daily for 6 months can be given in cases of INH intolerance or for contacts of patients with INH resistant TB. Drug sensitivities should always be checked when the source case is known. Rifampin will turn urine and other body fluids orange and ...
ISPO 2006 - Fremantle
... Dr Julie Dockerty – the course & complications of meningococcal disease ...
... Dr Julie Dockerty – the course & complications of meningococcal disease ...
Omni Bio Pharmaceutical, Inc. Creating Breakthrough Therapies Company Overview
... Fc-AAT Highlights – Inflammation (3) Fc-AAT 50 mcg at least as effective as p-AAT 2 mg and competitive with high-dose IL1-Ra (anakinra) in gout model p<0.001 ...
... Fc-AAT Highlights – Inflammation (3) Fc-AAT 50 mcg at least as effective as p-AAT 2 mg and competitive with high-dose IL1-Ra (anakinra) in gout model p<0.001 ...
Study Seeks Women`s Insights on What Works Best
... nine medical centers across the country. Participating women will be asked at annual intervals specific questions about the treatments they’ve elected to receive, and how well the treatments seem to be working for them. Approximately three years after initial treatment, researchers at the Duke Clini ...
... nine medical centers across the country. Participating women will be asked at annual intervals specific questions about the treatments they’ve elected to receive, and how well the treatments seem to be working for them. Approximately three years after initial treatment, researchers at the Duke Clini ...
July 1
... http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-15-009.html - to stimulate research in areas that are understudied, neglected, paradoxical, and/or have been difficult to address; 1. For tumors that arise from a premalignant field, what properties of cells in this field can be used to design str ...
... http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-15-009.html - to stimulate research in areas that are understudied, neglected, paradoxical, and/or have been difficult to address; 1. For tumors that arise from a premalignant field, what properties of cells in this field can be used to design str ...
Aplidin® shows positive results in pivotal Phase III clinical trial for
... Madrid, 31st of March, 2016 – PharmaMar (MSE:PHM) today announced positive top-line results of its Phase III clinical trial -ADMYRE- with Aplidin® (plitidepsin) in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma (MM). Aplidin® has shown ...
... Madrid, 31st of March, 2016 – PharmaMar (MSE:PHM) today announced positive top-line results of its Phase III clinical trial -ADMYRE- with Aplidin® (plitidepsin) in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma (MM). Aplidin® has shown ...